Pediatrix Medical Group, Inc. (NYSE:MD) Receives $10.90 Consensus PT from Analysts

Shares of Pediatrix Medical Group, Inc. (NYSE:MD) have earned a consensus rating of “Hold” from the five brokerages that are currently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $10.90.

Several research analysts have recently commented on MD shares. StockNews.com raised shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a report on Wednesday, August 7th. Jefferies Financial Group raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating and raised their target price for the stock from $8.00 to $14.00 in a report on Thursday, September 26th. Truist Financial raised their target price on shares of Pediatrix Medical Group from $10.00 to $13.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Finally, UBS Group raised their target price on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a report on Friday, August 9th.

Insider Buying and Selling

In other Pediatrix Medical Group news, Director Laura A. Linynsky sold 7,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now owns 30,805 shares in the company, valued at $343,783.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, Director Laura A. Linynsky sold 7,000 shares of the business’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total transaction of $78,120.00. Following the sale, the director now owns 30,805 shares in the company, valued at $343,783.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO C Marc Richards sold 17,438 shares of the business’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $10.08, for a total value of $175,775.04. Following the sale, the chief financial officer now owns 175,347 shares in the company, valued at $1,767,497.76. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 68,100 shares of company stock worth $701,889. Corporate insiders own 2.00% of the company’s stock.

Institutional Investors Weigh In On Pediatrix Medical Group

A number of hedge funds and other institutional investors have recently bought and sold shares of MD. Rubric Capital Management LP grew its position in shares of Pediatrix Medical Group by 797.0% in the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock valued at $61,532,000 after buying an additional 7,241,400 shares during the last quarter. Dana Investment Advisors Inc. grew its position in shares of Pediatrix Medical Group by 80.3% in the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock valued at $7,725,000 after buying an additional 455,785 shares during the last quarter. Boston Partners grew its position in shares of Pediatrix Medical Group by 34.0% in the 1st quarter. Boston Partners now owns 1,786,434 shares of the company’s stock valued at $17,702,000 after buying an additional 453,254 shares during the last quarter. Cubist Systematic Strategies LLC grew its position in shares of Pediatrix Medical Group by 639.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock valued at $2,192,000 after buying an additional 251,072 shares during the last quarter. Finally, ClariVest Asset Management LLC bought a new stake in shares of Pediatrix Medical Group in the 2nd quarter valued at about $1,721,000. Institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Stock Down 2.7 %

Pediatrix Medical Group stock opened at $12.55 on Thursday. The stock has a market cap of $1.06 billion, a P/E ratio of -14.76, a P/E/G ratio of 1.98 and a beta of 1.56. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.87. Pediatrix Medical Group has a twelve month low of $6.62 and a twelve month high of $12.99. The company’s 50-day moving average price is $11.31 and its two-hundred day moving average price is $9.23.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.03. Pediatrix Medical Group had a negative net margin of 12.58% and a positive return on equity of 10.59%. The firm had revenue of $504.30 million for the quarter, compared to analysts’ expectations of $505.49 million. During the same period in the prior year, the firm earned $0.37 EPS. The business’s revenue was up .7% on a year-over-year basis. As a group, analysts expect that Pediatrix Medical Group will post 1.19 EPS for the current year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.